AstraZeneca PLC (FRA:ZEG)
Germany · Delayed Price · Currency is EUR | Market Cap | 258.06B +15.5% |
| Revenue (ttm) | 50.03B +8.6% |
| Net Income | 8.71B +45.3% |
| EPS | 5.57 +45.3% |
| Shares Out | n/a |
| PE Ratio | 29.63 |
| Forward PE | 18.45 |
| Dividend | 2.71 (1.63%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 1,871 |
| Average Volume | 1,039 |
| Open | 166.65 |
| Previous Close | 166.55 |
| Day's Range | 165.55 - 168.00 |
| 52-Week Range | 113.25 - 180.45 |
| Beta | n/a |
| RSI | 46.24 |
| Earnings Date | Apr 29, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsNews
Abivax (ABVX) Shares Surge Amid Denial of AstraZeneca Takeover Report
Abivax (ABVX) Shares Surge Amid Denial of AstraZeneca Takeover Report
AZN Stock Experiences Slight Dip in Morning Trading
AZN Stock Experiences Slight Dip in Morning Trading
AstraZeneca (AZN) Refutes Takeover Speculation
AstraZeneca (AZN) Refutes Takeover Speculation
AstraZeneca (AZN) Obtains Exclusive Negotiation Period with Abivax
AstraZeneca (AZN) Obtains Exclusive Negotiation Period with Abivax
AstraZeneca (AZN) Engages in Exclusive Takeover Talks with Abivax
AstraZeneca (AZN) Engages in Exclusive Takeover Talks with Abivax
AstraZeneca (AZN) Enters Exclusive Agreement Boosting Abivax Shares
AstraZeneca (AZN) Enters Exclusive Agreement Boosting Abivax Shares
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
British drugmaker AstraZeneca Plc (NYSE: AZN) has emerged as the leading contender to acquire French biotech Abivax SA (NASDAQ: ABVX), following the company's dramatic valuation surge after strong cli...
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
British drugmaker AstraZeneca Plc (NYSE: AZN) has emerged as the leading contender to acquire French biotech Abivax SA (NASDAQ: ABVX), following the company's dramatic valuation surge after strong c...
Health Rounds: Death from dementia on the rise among people with type 2 diabetes
In people with type 2 diabetes in the world's richest countries, deaths from cardiovascular disease are declining while mortality from dementia is on the rise, a large analysis has found.
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Joshua Jackson have teamed up as part of a national public health campaign designed to encourage fans to Get Body Checked Against Cancer and be proac...
Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn
UK’s GSK is leading the way in research but AstraZeneca is not involved in the area, report finds Business live – latest updates The pipeline of drugs to fight superbugs remains “worryingly thin” and ...
AstraZeneca Announces Approval Of Koselugo In Canada
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said Alexion, AstraZeneca Rare Disease's Koselugo has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 who...
AstraZeneca (AZN) Achieves Priority Review for Enhertu in Breast Cancer Treatment
AstraZeneca (AZN) Achieves Priority Review for Enhertu in Breast Cancer Treatment
Daiichi Sankyo: FDA Grants Priority Review For ENHERTU
(RTTNews) - Daiichi Sankyo (4568.T) and AstraZeneca's (AZN, AZN.L, ZEG.DE, AZN.ST) supplemental Biologics License Application for ENHERTU has been accepted and granted Priority Review in the U.S. for ...
AstraZeneca (AZN) and Other Drugmakers Watch as Key FDA Official Resigns
AstraZeneca (AZN) and Other Drugmakers Watch as Key FDA Official Resigns
The Zacks Analyst Blog Highlights Exxon Mobil, Palantir, AstraZeneca, Gencor Industries and Hour Loop
Exxon Mobil, Palantir and AstraZeneca lead Zacks' latest analyst reports, highlighting strong production growth, AI momentum and a robust drug pipeline.
Pay bonanza for blue chip bosses: Rolls-Royce chief 'Turbo' Tufan set for £24m as GSK's Walmsley scoops £15.7m
Erginbilgic, pictured, has led a stunning turnaround, and has been rewarded with a deal that puts him on course to rival AstraZeneca chief Pascal Soriot.
Top Analyst Reports for Exxon Mobil, Palantir & AstraZeneca
Exxon Mobil leads fresh analyst reports as Permian and Guyana output power growth, while Palantir's AI platforms and AstraZeneca's drug pipeline highlight key momentum.
Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor
On Wednesday, Xencor Inc. (NASDAQ: XNCR) said it is revising its revenue outlook for royalties tied to Ultomiris . The company announced that its licensee, Alexion Pharmaceuticals, Inc. , has stated ...
GLP-1 drugs protect against new or worsening addictions, large study shows
Ozempic, Mounjaro and other GLP-1 drugs for diabetes can prevent the formation of new substance use disorders and alleviate existing addictions, according to findings from a large study of U.S. milit...
AstraZeneca (AZN) Strengthens Clinical Portfolio and Expands Investment Horizons
AstraZeneca (AZN) Strengthens Clinical Portfolio and Expands Investment Horizons
If You Invested $100 In AstraZeneca Stock 5 Years Ago, You Would Have This Much Today
AstraZeneca (NYSE: AZN) has outperformed the market over the past 5 years by 4.19% on an annualized basis producing an average annual return of 16.3%. Currently, AstraZeneca has a market capitalizati...
Baron International Growth Fund Q4 2025: Contributors, Detractors, And Trades
For 2025, we underperformed the Benchmark, while to a lesser extent also trailing our all-cap international growth Proxy Benchmark. The underperformance was in our view attributable to an abrupt but m...
AstraZeneca Prices $2 Bln Three Tranche Bond Offering
(RTTNews) - AstraZeneca PLC (AZN, AZN.L), a Swedish-British pharmaceutical and biotechnology company, on Thursday priced a three-tranche bond offering totalling $2 billion through its wholly owned sub...
AstraZeneca Launches “A.Catalyst Thailand Hub”: AI-Integrated Health Transformation
AstraZeneca (Thailand) Ltd., in collaboration with the public and private sectors, academia, and patient networks, has officially launched the A.Catalyst Network Thailand Hub. This global health innov...